Fennec PharmaceuticalsFENC
FENC
About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Employees: 32
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
6% more funds holding
Funds holding: 64 [Q4 2024] → 68 (+4) [Q1 2025]
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
9.98% less ownership
Funds ownership: 58.51% [Q4 2024] → 48.53% (-9.98%) [Q1 2025]
20% less capital invested
Capital invested by funds: $101M [Q4 2024] → $81.6M (-$19.9M) [Q1 2025]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
64%
upside
Avg. target
$13
64%
upside
High target
$13
64%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 64%upside $13 | Buy Reiterated | 20 May 2025 |
Craig-Hallum Chase Knickerbocker | 64%upside $13 | Buy Maintained | 14 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
Neutral
Seeking Alpha
1 month ago
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen.
Negative
Zacks Investment Research
1 month ago
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.41 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
2 months ago
Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Seeking Alpha
3 months ago
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call.
Negative
Zacks Investment Research
3 months ago
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~
Neutral
GlobeNewsWire
3 months ago
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Charts implemented using Lightweight Charts™